CFDB - Cystic Fibrosis DataBase

  1. Home
  2. Database
Search (?)
at least one term
all terms
Advanced search
primary studies published RCT

Pulmonary delivery of tobramycin by an investigational EFlow electronic nebulizer saves 50% of the drug, and results in equivalent or improved tobramycin safety levels in plasma and sputum [abstract].

  • Year: 2009
  • Date: 2009
  • Author: Griese M
Source

Pediatric Pulmonology 2009;44(S32):300, Abstract no: 252.

Study design (if review, criteria of inclusion for studies)

RCT, parallel group, multicentre.

Participants

78 people with CF; 42 children (8 - 17 yrs) and 36 adults (18 - 42 yrs).

Interventions

1. TOBI® (300 mg/5 ml delivered by PARI LC PLUS); 2. Tobramycin PARI (150 mg/1.5 ml, delivered by an investigational eFlow), twice daily for 28 days.

Outcome measures

Sputum concentration of tobramycin at 7 days of use. Serum levels of tobramycin at 7 days of use. Adverse events. Nebulisation time.

Keywords: Anti-Bacterial Agents; Inhalation OR nebulised; pharmacological_intervention; Tobramycin; Bacterial Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Infection; Aminoglycosides; nebuliser; non pharmacological intervention - devices OR physiotherapy;